SCHEMBL5646100

SCHEMBL5646100

Nc1ncccc1NCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.68
APP P05067 2/20 0.51
ASPH Q12797 2/20 0.45
KDM8 Q8N371 2/20 0.45
KDM4E B2RXH2 1/20 0.45
RIOX2 Q8IUF8 1/20 0.45
HDAC1 Q13547 2/20 0.45
USP1 O94782 1/20 0.45
WDR48 Q8TAF3 1/20 0.45
CSF1R P07333 1/20 0.45
KIT P10721 1/20 0.45
KDR P35968 2/20 0.44
EGFR P00533 1/20 0.44
AURKA O14965 1/20 0.44
RPS6KB1 P23443 1/20 0.44
AURKB Q96GD4 1/20 0.44
FLT1 P17948 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11095805 0.83 BACE1 (0.73) BACE1APPKDM4EHDAC1RPS6KB1
SCHEMBL5646095 0.82 APP (0.56) BACE1APPASPHKDM8HDAC1
SCHEMBL11069733 0.81 BACE1 (1.00) BACE1APPKDM4EHDAC1EGFR
SCHEMBL21427815 0.80 BACE1 (0.73) BACE1APPKDM4EHDAC1
SCHEMBL30996046 0.80 HDAC6 (0.63) KDM4EHDAC1USP1WDR48HDAC3
SCHEMBL8264991 0.79 BACE1 (0.82) BACE1HDAC1RPS6KB1
SCHEMBL7939887 0.78 BACE1 (0.59) BACE1KDM4ECSF1RKITKDR
SCHEMBL7804114 0.76 BACE1 (0.62) BACE1RPS6KB1CACNA1BEPHX2
SCHEMBL14554976 0.76 CYP1A2 (0.59) APPUSP1WDR48CSF1RKIT
SCHEMBL29580175 0.74 CXCR4 (0.74) APPKDM4EHDAC1CSF1RKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265128-B2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO., INC. (US) 2007-09-04 US disclosed
US-20060069116-A1 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME LLC 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069116-A1 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes DPP4, DPP3, DPP7 BACE1 940/4885APP 576/4885ASPH 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.